| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Institute for Pathology and Urologic Clinics, University of Basel, CH-4031 Basel, [R. S., J. R., U. W., A. F., J. B., P. S., H. M., M. J. M., G. S.]; Institute for Pathology [U. S.] and Urologic Clinics [D. A.], Cantonal Hospital, CH-9007 St. Gallen; Institute for Pathology [R. M.] and Urologic Clinics [G. A.], City Hospital Triemli, CH-8063 Zürich; Urologic Clinics, Limmattal Hospital, CH-8952 Schlieren [H. K.]; Clara Hospital, CH-4031 Basel [M. R.]; Institute for Pathology [M. A.] and Urologic Clinics [F. H.], Cantonal Hospital, CH-5400 Baden; Institute for Pathology [T. H.] and Urologic Clinics [A. S.], Cantonal Hospital, Münsterlingen CH-8596 Scherzingen; Institute for Pathology [R. F.] and Urologic Clinics [P. J.], Cantonal Hospital, CH-8401 Winterthur; Urologic Clinics, Cantonal Hospital, CH-8208 Schaffhausen [J. L. F.]; Urologic Clinics, Cantonal Hospital, CH-4410 Liestal [T. G.], Switzerland; and Vysis Incorporated, Downers Grove, Illinois 60515-5400 [K. W.]
Studies by comparative genomic hybridization revealed that the chromosomal regions 3p25 and 8p11-p12 are recurrently amplified in bladder cancer. To investigate the prevalence of DNA copy number alterations in these chromosomal regions and study their clinical significance, we used probes for the RAF1 (3p25) and FGFR1 (8p12) genes for fluorescence in situ hybridization. A tissue microarray containing 2317 tumors was analyzed. The analysis revealed RAF1 amplification in 4.0% and FGFR1 amplification in 3.4% of interpretable tumors. In addition, deletions were found at the 3p25 locus in 2.2% and at the 8p11–12 locus in 9.9% of interpretable tumors. Both amplifications and deletions of RAF1 and FGFR1 were significantly associated with high tumor grade (P < 0.0001), advanced stage (P < 0.0001), and poor survival (P < 0.05) if tumors of all of the stages where analyzed together. RAF1 amplifications were associated with subsequent tumor progression in pT1 carcinomas (P < 0.05). The marked differences in the frequency of all of the analyzed changes between pTa grade 1/grade 2 and pT1–4 carcinomas support the concept of these tumor groups representing different tumor entities.
This article has been cited by other articles:
|
|
 |
|
  D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer Cancer Res., June 1, 2009; 69(11): 4613 - 4620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tonon, K.-K. Wong, G. Maulik, C. Brennan, B. Feng, Y. Zhang, D. B. Khatry, A. Protopopov, M. J. You, A. J. Aguirre, et al. High-resolution genomic profiles of human lung cancer PNAS, July 5, 2005; 102(27): 9625 - 9630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhao, B. A. Weir, T. LaFramboise, M. Lin, R. Beroukhim, L. Garraway, J. Beheshti, J. C. Lee, K. Naoki, W. G. Richards, et al. Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis Cancer Res., July 1, 2005; 65(13): 5561 - 5570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. TONON, C. BRENNAN, A. PROTOPOPOV, G. MAULIK, B. FENG, Y. ZHANG, D.B. KHATRY, M.J. YOU, A.J. AGUIRRE, E.S. MARTIN, et al. Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 11 - 24. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Nakao, K. R. Mehta, J. Fridlyand, D. H. Moore, A. N. Jain, A. Lafuente, J. W. Wiencke, J. P. Terdiman, and F. M. Waldman High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization Carcinogenesis, August 1, 2004; 25(8): 1345 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zheng, R. Simon, M. Mirlacher, R. Maurer, T. Gasser, T. Forster, P. A. Diener, M. J. Mihatsch, G. Sauter, and P. Schraml TRIO Amplification and Abundant mRNA Expression Is Associated with Invasive Tumor Growth and Rapid Tumor Cell Proliferation in Urinary Bladder Cancer Am. J. Pathol., July 1, 2004; 165(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Evans, B. L. Gallie, M. A.S. Jewett, G. R. Pond, K. Vandezande, J. Underwood, Y. Fradet, G. Lim, P. Marrano, M. Zielenska, et al. Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction Am. J. Pathol., January 1, 2004; 164(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Veltman, J. Fridlyand, S. Pejavar, A. B. Olshen, J. E. Korkola, S. DeVries, P. Carroll, W.-L. Kuo, D. Pinkel, D. Albertson, et al. Array-based Comparative Genomic Hybridization for Genome-Wide Screening of DNA Copy Number in Bladder Tumors Cancer Res., June 1, 2003; 63(11): 2872 - 2880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Mao, G. Orchard, D. M. Lillington, R. Russell-Jones, B. D. Young, and S. J. Whittaker Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas Blood, February 15, 2003; 101(4): 1513 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Sauter and M Mirlacher Tissue microarrays for predictive molecular pathology J. Clin. Pathol., August 1, 2002; 55(8): 575 - 576. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
